Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis C | 12 | 2025 | 256 | 3.310 |
Why?
|
| HIV Infections | 22 | 2025 | 3195 | 1.960 |
Why?
|
| Mass Screening | 11 | 2025 | 1361 | 1.850 |
Why?
|
| Hepacivirus | 9 | 2025 | 242 | 1.370 |
Why?
|
| Anti-HIV Agents | 7 | 2025 | 912 | 1.290 |
Why?
|
| Pre-Exposure Prophylaxis | 6 | 2025 | 269 | 1.200 |
Why?
|
| Drug Users | 1 | 2024 | 43 | 0.790 |
Why?
|
| Emergency Service, Hospital | 10 | 2025 | 2383 | 0.650 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 2020 | 49 | 0.620 |
Why?
|
| Tenofovir | 2 | 2020 | 301 | 0.590 |
Why?
|
| Emtricitabine | 1 | 2020 | 210 | 0.580 |
Why?
|
| HIV | 4 | 2025 | 251 | 0.510 |
Why?
|
| Continuity of Patient Care | 2 | 2019 | 297 | 0.470 |
Why?
|
| Coinfection | 2 | 2021 | 143 | 0.460 |
Why?
|
| Choice Behavior | 1 | 2016 | 180 | 0.410 |
Why?
|
| Viral Load | 2 | 2025 | 526 | 0.400 |
Why?
|
| Patient Preference | 1 | 2016 | 223 | 0.390 |
Why?
|
| Sexual Health | 2 | 2024 | 68 | 0.380 |
Why?
|
| Fasciola hepatica | 1 | 2012 | 2 | 0.360 |
Why?
|
| Topography, Medical | 1 | 2012 | 10 | 0.360 |
Why?
|
| Fascioliasis | 1 | 2012 | 3 | 0.360 |
Why?
|
| Anti-Retroviral Agents | 1 | 2014 | 251 | 0.360 |
Why?
|
| Opioid-Related Disorders | 1 | 2020 | 605 | 0.350 |
Why?
|
| Syphilis | 2 | 2024 | 38 | 0.350 |
Why?
|
| RNA, Viral | 4 | 2025 | 693 | 0.340 |
Why?
|
| Hospitalization | 4 | 2025 | 2461 | 0.320 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2024 | 883 | 0.310 |
Why?
|
| Humans | 39 | 2025 | 145783 | 0.310 |
Why?
|
| Patient Compliance | 1 | 2014 | 588 | 0.310 |
Why?
|
| Adult | 21 | 2025 | 40881 | 0.300 |
Why?
|
| Middle Aged | 19 | 2025 | 36309 | 0.280 |
Why?
|
| Antiviral Agents | 3 | 2025 | 769 | 0.260 |
Why?
|
| Male | 26 | 2025 | 73011 | 0.250 |
Why?
|
| Prospective Studies | 7 | 2025 | 8078 | 0.250 |
Why?
|
| Pragmatic Clinical Trials as Topic | 2 | 2024 | 133 | 0.250 |
Why?
|
| Colorado | 4 | 2024 | 4556 | 0.240 |
Why?
|
| Equivalence Trials as Topic | 2 | 2023 | 35 | 0.240 |
Why?
|
| Female | 24 | 2025 | 79045 | 0.230 |
Why?
|
| Drug Utilization Review | 1 | 2025 | 61 | 0.220 |
Why?
|
| Drug Substitution | 1 | 2025 | 63 | 0.220 |
Why?
|
| HIV-1 | 3 | 2021 | 908 | 0.210 |
Why?
|
| Prevalence | 2 | 2022 | 2875 | 0.210 |
Why?
|
| Urethritis | 1 | 2023 | 4 | 0.200 |
Why?
|
| Mycoplasma genitalium | 1 | 2023 | 3 | 0.200 |
Why?
|
| Proctitis | 1 | 2023 | 6 | 0.200 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2025 | 279 | 0.200 |
Why?
|
| Uterine Cervicitis | 1 | 2023 | 7 | 0.200 |
Why?
|
| Mycoplasma Infections | 1 | 2023 | 17 | 0.200 |
Why?
|
| Pelvic Inflammatory Disease | 1 | 2023 | 12 | 0.200 |
Why?
|
| Trench Fever | 1 | 2022 | 5 | 0.190 |
Why?
|
| Bartonella quintana | 1 | 2022 | 5 | 0.190 |
Why?
|
| Endocarditis | 1 | 2022 | 40 | 0.180 |
Why?
|
| Lymphedema | 1 | 2021 | 22 | 0.170 |
Why?
|
| Housing | 1 | 2022 | 142 | 0.170 |
Why?
|
| Cost-Benefit Analysis | 1 | 2024 | 644 | 0.160 |
Why?
|
| Homosexuality, Male | 2 | 2021 | 231 | 0.160 |
Why?
|
| Safe Sex | 1 | 2020 | 24 | 0.160 |
Why?
|
| Focus Groups | 1 | 2024 | 572 | 0.160 |
Why?
|
| Patient Selection | 1 | 2024 | 739 | 0.160 |
Why?
|
| Particulate Matter | 1 | 2023 | 326 | 0.160 |
Why?
|
| Qualitative Research | 2 | 2025 | 1683 | 0.150 |
Why?
|
| Community Health Centers | 1 | 2019 | 59 | 0.150 |
Why?
|
| Health Plan Implementation | 1 | 2020 | 141 | 0.150 |
Why?
|
| Syphilis Serodiagnosis | 1 | 2019 | 5 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2023 | 1752 | 0.150 |
Why?
|
| United States | 7 | 2025 | 16126 | 0.150 |
Why?
|
| Treponema pallidum | 1 | 2019 | 10 | 0.150 |
Why?
|
| Hospitals | 1 | 2024 | 733 | 0.140 |
Why?
|
| Darunavir | 1 | 2019 | 20 | 0.140 |
Why?
|
| Health Services Accessibility | 2 | 2024 | 1101 | 0.140 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2019 | 44 | 0.140 |
Why?
|
| HIV Protease Inhibitors | 1 | 2019 | 69 | 0.140 |
Why?
|
| Self-Management | 1 | 2021 | 204 | 0.140 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 288 | 0.140 |
Why?
|
| Administration, Oral | 1 | 2020 | 867 | 0.130 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2019 | 79 | 0.130 |
Why?
|
| Public Health Surveillance | 1 | 2018 | 83 | 0.130 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2020 | 303 | 0.120 |
Why?
|
| Reproductive Health | 1 | 2018 | 91 | 0.120 |
Why?
|
| Time-to-Treatment | 1 | 2019 | 251 | 0.120 |
Why?
|
| Electronic Health Records | 1 | 2024 | 1202 | 0.120 |
Why?
|
| Referral and Consultation | 2 | 2024 | 869 | 0.120 |
Why?
|
| Antibodies, Viral | 1 | 2020 | 674 | 0.120 |
Why?
|
| Program Evaluation | 1 | 2020 | 944 | 0.120 |
Why?
|
| Treatment Outcome | 3 | 2023 | 11794 | 0.120 |
Why?
|
| Attitude of Health Personnel | 1 | 2024 | 1197 | 0.120 |
Why?
|
| Ribavirin | 1 | 2016 | 81 | 0.120 |
Why?
|
| Sexual and Gender Minorities | 1 | 2019 | 265 | 0.100 |
Why?
|
| Hepatitis C, Chronic | 1 | 2016 | 153 | 0.100 |
Why?
|
| Drug Monitoring | 1 | 2018 | 401 | 0.100 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2014 | 280 | 0.100 |
Why?
|
| Time Factors | 3 | 2025 | 7134 | 0.100 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 5428 | 0.100 |
Why?
|
| Algorithms | 1 | 2021 | 1851 | 0.100 |
Why?
|
| Retrospective Studies | 6 | 2025 | 17330 | 0.100 |
Why?
|
| Primary Health Care | 2 | 2023 | 1737 | 0.090 |
Why?
|
| Delivery of Health Care | 2 | 2021 | 948 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 849 | 0.090 |
Why?
|
| Risk Factors | 4 | 2024 | 10919 | 0.090 |
Why?
|
| Life Cycle Stages | 1 | 2012 | 37 | 0.090 |
Why?
|
| Cohort Studies | 2 | 2019 | 6033 | 0.090 |
Why?
|
| Africa | 1 | 2012 | 119 | 0.090 |
Why?
|
| Adolescent | 5 | 2024 | 22577 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 1372 | 0.080 |
Why?
|
| Sofosbuvir | 2 | 2022 | 61 | 0.080 |
Why?
|
| Travel | 1 | 2012 | 136 | 0.080 |
Why?
|
| Population Surveillance | 1 | 2014 | 484 | 0.080 |
Why?
|
| Sexual Partners | 2 | 2024 | 194 | 0.080 |
Why?
|
| Socioeconomic Factors | 1 | 2014 | 1327 | 0.080 |
Why?
|
| Young Adult | 5 | 2024 | 14254 | 0.070 |
Why?
|
| Aged | 2 | 2019 | 26217 | 0.060 |
Why?
|
| Sustained Virologic Response | 1 | 2025 | 46 | 0.060 |
Why?
|
| Urban Health Services | 1 | 2025 | 69 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2021 | 2000 | 0.060 |
Why?
|
| Organizational Case Studies | 1 | 2025 | 69 | 0.060 |
Why?
|
| New Orleans | 1 | 2024 | 19 | 0.050 |
Why?
|
| Demography | 1 | 2024 | 282 | 0.050 |
Why?
|
| Macrolides | 1 | 2023 | 67 | 0.050 |
Why?
|
| Triage | 1 | 2025 | 250 | 0.050 |
Why?
|
| Ambulatory Care Facilities | 1 | 2024 | 269 | 0.040 |
Why?
|
| Polyphosphates | 1 | 2022 | 43 | 0.040 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2023 | 185 | 0.040 |
Why?
|
| Anthropology, Cultural | 1 | 2021 | 27 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2021 | 79 | 0.040 |
Why?
|
| Nasopharynx | 1 | 2021 | 72 | 0.040 |
Why?
|
| Dried Blood Spot Testing | 1 | 2022 | 126 | 0.040 |
Why?
|
| Pregnancy | 2 | 2024 | 7216 | 0.040 |
Why?
|
| Fluorenes | 1 | 2020 | 45 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2022 | 413 | 0.040 |
Why?
|
| Community-Based Participatory Research | 1 | 2022 | 168 | 0.040 |
Why?
|
| Genotype | 1 | 2025 | 1857 | 0.040 |
Why?
|
| Protease Inhibitors | 1 | 2020 | 102 | 0.040 |
Why?
|
| Alanine | 1 | 2020 | 169 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2021 | 183 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 5925 | 0.040 |
Why?
|
| Public Health | 1 | 2024 | 574 | 0.040 |
Why?
|
| Saliva | 1 | 2021 | 249 | 0.040 |
Why?
|
| Reagins | 1 | 2019 | 2 | 0.040 |
Why?
|
| Benzimidazoles | 1 | 2020 | 189 | 0.040 |
Why?
|
| Length of Stay | 1 | 2025 | 1350 | 0.040 |
Why?
|
| Oxazines | 1 | 2019 | 37 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2021 | 1083 | 0.030 |
Why?
|
| Research Design | 1 | 2024 | 1139 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2022 | 892 | 0.030 |
Why?
|
| Adenine | 1 | 2020 | 339 | 0.030 |
Why?
|
| Chicago | 1 | 2018 | 62 | 0.030 |
Why?
|
| Pyridones | 1 | 2019 | 209 | 0.030 |
Why?
|
| Logistic Models | 1 | 2021 | 2139 | 0.030 |
Why?
|
| Piperazines | 1 | 2019 | 375 | 0.030 |
Why?
|
| Community Health Services | 1 | 2018 | 231 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 1043 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2025 | 3752 | 0.030 |
Why?
|
| Physicians | 1 | 2024 | 956 | 0.030 |
Why?
|
| Animals | 2 | 2021 | 38102 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2019 | 1898 | 0.020 |
Why?
|
| Parents | 1 | 2021 | 1407 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2023 | 1925 | 0.020 |
Why?
|
| Caregivers | 1 | 2021 | 1074 | 0.020 |
Why?
|
| Child | 2 | 2021 | 22740 | 0.020 |
Why?
|